MENA v. TEVA PHARMACEUTICALS USA, INC. et al
| JASMINE MENA |
| Teva Pharmaceuticals USA Inc, Teva Women's Health LLC doing business as Teva Women's Health Inc, DURAMED PHARMACEUTICALS, INC. A DIVISION OF BARR PHARMACEUTICALS, INC. doing business as TEVA WOMEN'S HEALTH, Teva Women's Health Inc, Teva Women's Health LLC, TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., Coopersurgical Inc and The Cooper Companies Inc |
| 1:2022cv02354 |
| June 14, 2022 |
| US District Court for the Northern District of Georgia |
| Leigh Martin May |
| Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability |
| 28 U.S.C. § 1332 Diversity-Product Liability |
| Both |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 14, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 18 AMENDED COMPLAINT Short Form Complaint against Coopersurgical Inc, TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., Teva Pharmaceuticals USA Inc, Teva Women's Health LLC, The Cooper Companies Incwith Jury Demand filed by JASMINE MENA. (Attachments: #1 Civil Cover Sheet, #2 Summons Coopersurgical, Inc., #3 Summons Teva Branded Pharmaceutical Products R&D, Inc., #4 Summons The Cooper Companies, Inc., #5 Summons Teva Pharmaceuticals USA, Inc., #6 Summons Teva Women's Health, LLC)(Kassan, Randi) Please visit our website at http://www.gand.uscourts.gov/commonly-used-forms to obtain Pretrial Instructions and Pretrial Associated Forms which includes the Consent To Proceed Before U.S. Magistrate form. |
Filing 17
ORDER INITIAL CONFERENCE: The Court held its Initial Conference in this MDL on February 9, 2021. The below are the orders entered after discussion of these issues at that conference. 1. Leadership structure: After the Court discussed issues concerning the leadership structure with all parties, the Court ORDERED Plaintiffs and Defendants to each file their proposed consent motion and order as to their requested leadership structure and team within 7 days of the date of this order. 2. Future status conferences: The Court will hold status conferences once a month. The next six conferences will take place on the following dates at 10:00 am via zoom: Tuesday, March 9, 2021; Monday, April 12, 2021; Wednesday, May 12, 2021; Monday, June 14, 2021; Tuesday, July 13, 2021; Friday, August 20, 2021. The Court will send out the zoom links prior to the conferences. The parties will submit a proposed consent agenda 3 business days prior to the conference. The parties will also confer as to the format for presenting issues that require additional explanation. When these are necessary, they should also be filed 3 business days before the conference. 3. Stay of responsive pleading obligations: The Court continues the stay of responsive pleading obligations provided for in Section 6(b) of the Courts initial order. 4. Pending motions: The Court DENIES WITHOUT PREJUDICE all pending motions in the individual cases comprising the MDL. These cases are also ADMINISTRATIVELY CLOSED. These terminated motions will later be refiled in accordance with an upcoming Case Management Order. 5. Docketing: All parties are to docket future filings only in the MDL case. The case caption should indicate whether any filing applies to all cases or list the individual cases to which it should apply. 6. Electronic service: The Court ORDERS all attorneys participating in the MDL proceeding to register with the Courts CM/ECF system. Because all attorneys will then receive electronic copies of documents filed in the MDL, the Court ORDERS that electronic service of documents via the Courts CM/ECF system satisfies the obligation of service. Hereafter, unless otherwise ordered, neither the clerks office nor counsel for the parties shall be obligated to provide service copies of any filings or related orders by U.S. Mail or any other means to attorneys who have not registered with the Courts CM/ECF system. An attorney who is not participating in the MDL and does not want to receive CM/ECF notifications may file a motion to withdraw or a certificate of consent to withdraw in accordance with Local Rule 83.1(E). 7. Initial disclosures: The Court GRANTS the parties joint request for the Court to excuse the parties from Rule 26(f) initial disclosures; except as to the ParaGard New Drug Application (NDA) that was transferred on or about November 10, 2005, to Duramed Pharmaceuticals, Inc., and produced by TWH, Inc., to plaintiff in the Estrada case. 8. Case management and initial orders: The parties are ORDERED to confer as to proposed orders for the list found herein. See order for further specifics and instructions. Signed by Judge Leigh Martin May on 2/10/2021. (kxm)
|
| Filing 16 Case transferred in from District of Pennsylvania Eastern; Case Number 2:22-cv-02115. Original file certified copy of transfer order and docket sheet received. |
| Civil Case Terminated. (kxm) |
| Notification of Docket Correction: Case opened with the wrong case number. The correct case number is 1:22-cv-2354 LMM (aar) |
| Filing 15 Certified Copy of Conditional Transfer Order 46. Re: Order that, pursuant to Rule 7.1 of the Rules of Procedure of the U.S. Judicial Panel on MDL, the action is transferred under 28 USC sec. 1407 to the Northern District of Georgia for the reasons stated in the order of December 16, 2020, and, with the consent of that court, assigned to the Hon. Leigh Martin May. (fdc) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Case transferred to U.S. District Court Northern District of Georgia via CM/ECF electronic transfer. (fdc) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 14 ANSWER to Complaint by TEVA WOMEN'S HEALTH INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 13 ANSWER to Complaint by TEVA PHARMACEUTICALS USA, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 12 ANSWER to Complaint by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 11 ANSWER to Complaint by COOPERSURGICAL, INC.,.(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 10 ANSWER to Complaint by THE COOPER COMPANIES, INC.,.(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 9 Original Record together with certified copy of docket entries received from Court of Common Pleas of Philadelphia County. (ke) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 8 ANSWER to Complaint by TEVA WOMEN'S HEALTH, LLC., individually and as successor in interest to TEVA WOMEN'S HEALTH, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 7 Disclosure Statement Form pursuant to FRCP 7.1 by TEVA WOMEN'S HEALTH, LLC., individually and as successor in interest to TEVA WOMEN'S HEALTH, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 6 Disclosure Statement Form pursuant to FRCP 7.1 by TEVA WOMEN'S HEALTH INC., individually, and as successor in interst to, DURAMED PHARMACEUTICALS, INC., a division of Barr Pharmaceuticals, Inc..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 5 Disclosure Statement Form pursuant to FRCP 7.1 by TEVA PHARMACEUTICALS USA, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 4 Disclosure Statement Form pursuant to FRCP 7.1 by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 3 Disclosure Statement Form pursuant to FRCP 7.1 by COOPERSURGICAL, INC.,.(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 2 Disclosure Statement Form pursuant to FRCP 7.1 by THE COOPER COMPANIES, INC.,.(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
| Filing 1 NOTICE OF REMOVAL by TEVA WOMEN'S HEALTH, LLC., individually and as successor in interest to TEVA WOMEN'S HEALTH, INC., TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., THE COOPER COMPANIES, INC.,, TEVA PHARMACEUTICALS USA, INC., COOPERSURGICAL, INC.,, TEVA WOMEN'S HEALTH INC., individually, and as successor in interst to, DURAMED PHARMACEUTICALS, INC., a division of Barr Pharmaceuticals, Inc. (Filing fee $ 402 receipt number APAEDC-15951902), filed by TEVA WOMEN'S HEALTH, LLC., individually and as successor in interest to TEVA WOMEN'S HEALTH, INC., TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., THE COOPER COMPANIES, INC.,, TEVA PHARMACEUTICALS USA, INC., COOPERSURGICAL, INC.,, TEVA WOMEN'S HEALTH INC., individually, and as successor in interst to, DURAMED PHARMACEUTICALS, INC., a division of Barr Pharmaceuticals, Inc..(RUBENSTEIN, BRIAN) [Transferred from Pennsylvania Eastern on 6/14/2022.] |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Georgia Northern District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
